Resistin, Visfatin, Adiponectin, and Leptin: Risk of Breast Cancer in Pre- and Postmenopausal Saudi Females and Their Possible Diagnostic and Predictive Implications as Novel Biomarkers
Table 2
Anthropometric measurements, metabolic, and adipokines serum levels among all groups.
Premenopause
Postmenopause
Healthy control
Breast cancer
Healthy control
Breast cancer
( = 27)
( = 44)
( = 41)
( = 38)
Age (years)
35.22 ± 7.59
43.68 ± 6.07a
63.46 ± 10.04
65.26 ± 11.34a
BMI (kg/m2)
23.72 ± 1.26
24.04 ± 1.24
24.22 ± 1.42
24.92 ± 1.51
WC (cm)
76.71 ± 2.91
76.21 ± 3.39
76.09 ± 3.15
79.05 ± 2.59a
SBP (mmHg)
123.29 ± 9.31
124.43 ± 7.42
125.78 ± 9.08
131.10 ± 12.42a
DBP (mmHg)
77.37 ± 8.0
79.11 ± 9.06
82.73 ± 5.44
86.11 ± 10.40a
Glucose (mg/dL)
88.02 ± 10.39
88.80 ± 12.51
98.56 ± 11.68
98.60 ± 12.51
TG (mg/dL)
118.27 ± 29.97
151.50 ± 19.60
126.57 ± 25.37
153.88 ± 26.20
TC (mg/dL)
189.14 ± 23.17
204.52 ± 23.82
194.76 ± 12.718
224.52 ± 30.82
LDLc (mg/dL)
121.56 ± 19.55
142.94 ± 23.27
137.93 ± 23.49
147.52 ± 18.82
HDLc (mg/dL)
44.81 ± 5.37
39.91 ± 4.83
45.90 ± 5.41
40.89 ± 3.78
Leptin (ng/mL)
19.52 ± 2.93
20.32 ± 1.87
19.68 ± 1.19
29.52 ± 4.17
Adiponectin (mg/L)
10.86 ± 1.67
9.92 ± 0.62
11.01 ± 1.58
6.74 ± 1.92
Resistin (μg/L)
24.15 ± 1.24
25.21 ± 1.54
21.73 ± 2.79
27.14 ± 1.79
Visfatin (ng/mL)
15.03 ± 2.91
16.96 ± 1.99
15.26 ± 2.41
21.20 ± 3.62
< 0.05 as calculated by ANOVA -test versus respective controls (between premenopausal healthy control and premenopausal BC patients and between postmenopausal healthy control and postmenopausal BC patients).
